Last reviewed · How we verify

NCT07023705

MLPR As A Diagnostic Marker For Acute Pulmonary Embolism

Completed Last updated 19 June 2025
What this trial tests

trial testing Monocyte to Large Platelet Ratio (MLPR) in Pulmonary Embolism (Diagnosis) in 37 participants. Completed in 31 May 2025.

Timeline
1 January 2024
Primary endpoint
31 December 2024
31 May 2025

Quick facts

Lead sponsorAin Shams University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment37
Start date1 January 2024
Primary completion31 December 2024
Estimated completion31 May 2025
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Ain Shams University

Who can join

Eligibility, any sex, with Pulmonary Embolism (Diagnosis) or Diagnosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A retrospective study to assess the utility of hematological marker (monocyte to large platelet ratio) to diagnose patients with pulmonary embolism

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Pulmonary Embolism (Diagnosis)

Currently open trials in the same condition.

Other Ain Shams University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07023705.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing